Stephanie Maiocco
VP of Biotherapeutics Evercrisp
Stephanie Maiocco, is VP of biotherapeutics at evercrisp, and a scientist in Apple Tree Partners. She has designed, optimized, and executed laboratory experiments using a wide array of innovative in vitro methodologies and provided novel solutions to protein design and assay development. Stephanie has previously contributed to innovative protein technology platforms at both Akrevia Therapeutics and Elstar Therapeutics. She is a co-inventor on multiple patents for bi-specific antibodies and protein therapeutics.
Seminars
Wednesday 9th December 2026
AI-Engineered Miniproteins for Targeted Oligonucleotide Delivery: Enabling Receptor-Mediated Uptake Beyond the Liver
2:45 pm
- Showcase the application of AI-designed miniproteins for siRNA delivery to muscle, including evidence of functional target knockdown
- Examine the key challenges in translating receptor binding and cellular uptake into effective intracellular delivery and pharmacology
- Consider how targeted miniprotein delivery could expand the reach of oligonucleotide therapeutics to tissues and cell types that remain difficult to access
